Open AccessTHE CHARACTERISTICS OF ONCO-UROLOGICAL MORBIDITY OF MOSCOW POPULATION IN 2006-2015
Author(s) -
A. R. Gevorkyan
Publication year - 2019
Publication title -
zdravoohranenie rossijskoj federacii
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.164
H-Index - 3
eISSN - 2412-0723
pISSN - 0044-197X
DOI - 10.18821/0044-197x-2017-61-5-250-256
Subject(s) - medicine , prostate cancer , cancer , bladder cancer , population , disease , prostate , kidney cancer , oncology , gynecology , urology , environmental health
The article presents the analysis of trends specific for onco-urological morbidity of Moscow population on the basis of data of official statistical reports for 2006-2015. It is established that prostate cancer is the most actual onco-urological problem in Moscow. The level of morbidity of prostate cancer in the capital exceeds the corresponding average level in the Russian Federation. During 2006-2015, the morbidity of prostate cancer in Moscow increased up to 33.6% i.e. from 52.7 to 70.4 cases per 100 000 of male population. In Moscow, in 2015, morbidity of kidney cancer made up to 11.73 and bladder cancer - 9.72 cases per 100 000 of population. As compared with 2006, morbidity of prostate cancer decreased up to 3.1% and morbidity of bladder cancer increased up to 9.2%. In Moscow, for morbidity of prostate cancer and bladder cancer are specific lower levels in comparison with national average indices. It is demonstrated that efficiency of target oncologic preventive examinations, timeliness of detection of onco-urological diseases and also efficiency of their treatment in Moscow is higher than in the Russian Federation on the whole. At that, in Moscow 31.6% of cases of prostate cancer, 29,7% of cases of kidney cancer and 17.7% of bladder cancer are detected at stage III-IV of disease. The results of implemented study testify necessity of development of urological care of population, including its out-patient section that effects efficiency and timeliness of detection and effectiveness of treatment of onco-urological diseases.